PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference

MENLO PARK, Calif., Nov. 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at Piper Sandler's 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 11:30 AM ET in New York, NY.

GlobeNewsWire • Nov 28, 2025

Top 3 Genomics Stocks to Consider for Your Portfolio

Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.

Zacks Investment Research • Nov 18, 2025

Pacific Biosciences (PACB) Upgraded to Buy: Here's Why

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Nov 13, 2025

PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y

PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.

Zacks Investment Research • Nov 6, 2025

Pacific Biosciences of California, Inc. (PACB) Q3 2025 Earnings Call Transcript

Pacific Biosciences of California, Inc. ( PACB ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Christian Henry - President, CEO & Director James Gibson - Chief Financial Officer Conference Call Participants Carrie Mendivil - Gilmartin Group LLC Kyle Mikson - Canaccord Genuity Corp., Research Division Madeline Mollman - Wolfe Research, LLC Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Luke Sergott - Barclays Bank PLC, Research Division Benjamin Mee - Stephens Inc., Research Division Thomas Stevens - TD Cowen, Research Division Nathan Bolanos - UBS Investment Bank, Research Division Presentation Operator Good day, and welcome to the PacBio Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

Seeking Alpha • Nov 6, 2025

Compared to Estimates, Pacific Biosciences (PACB) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Pacific Biosciences (PACB) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Nov 6, 2025

Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.17 per share a year ago.

Zacks Investment Research • Nov 5, 2025

HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes

New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics

GlobeNewsWire • Nov 5, 2025

Pacific Biosciences (PACB) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Pacific Biosciences (PACB), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Zacks Investment Research • Nov 4, 2025

PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China

NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia

GlobeNewsWire • Nov 4, 2025